Trastuzumab deruxtecan: tested on its own
52 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (21), then studies with results posted, then the rest; newest registration first within each.
- A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer PatientsNot yet recruitingNCT07936422Phase 2Report a problem
- A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast CancerNot yet recruitingNCT07782086Not applicableReport a problem
- A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal CancerNot yet recruitingNCT07691489Phase 2Report a problem
- Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain MetastasesNot yet recruitingNCT07454668Phase 1Report a problem
- Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.RecruitingNCT07195344Phase 4Report a problem
- Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain MetastasesRecruitingNCT07134153Phase 1/2Report a problem
- Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI CancersNot yet recruitingNCT07126561Phase 2Report a problem
- A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant SettingRecruitingNCT07022483Phase 3Report a problem
- A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid TumorsRecruitingNCT07015697Phase 1Report a problem
- Trial of Trastuzumab Deruxtecan in Previously Treated HER2RecruitingNCT06750484Phase 2Report a problem
- A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular RelapseRecruitingNCT06643585Phase 3Report a problem
- Castrate Resistant Prostate Cancer Enhertu TherapyRecruitingNCT06610825Phase 2Report a problem
- T-DXd Versus THP for Medium-risk HER2-positive Early Breast CancerNot yet recruitingNCT06548178Phase 2Report a problem
- Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain MetastasesEnrolling by invitationNCT06250777Phase 2Report a problem
- A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)RecruitingNCT06174987Phase 3Report a problem
- Trastuzumab Deruxtecan (T-DXd) for People With Brain CancerRecruitingNCT06058988Phase 2Report a problem
- Basket Study for Oligo-metastatic Breast CancerRecruitingNCT05982678Phase 2Report a problem
- Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal CancerRecruitingNCT05965479Phase 2Report a problem
- T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low PatientsNot yet recruitingNCT05953168Phase 2Report a problem
- Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerRecruitingNCT05950945Phase 3Report a problem
- Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorRecruitingNCT04616560Phase 2Report a problem
- Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+PertuzumabTerminatedNCT05744375Phase 2Results postedReport a problem
- A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLCActive, not recruitingNCT05246514Phase 2Results postedReport a problem
- Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior RegimensCompletedNCT04989816Phase 2Results postedReport a problem
- A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast CancerActive, not recruitingNCT04739761Phase 3Results postedReport a problem
- Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT04644237Phase 2Results postedReport a problem
- A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating MutationsActive, not recruitingNCT04639219Phase 2Results postedReport a problem
- Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast CancerActive, not recruitingNCT04494425Phase 3Results postedReport a problem
- DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] DiseaseCompletedNCT04420598Phase 2Results postedReport a problem
- Testing the Biological Effects of DS-8201a on Patients With Advanced CancerActive, not recruitingNCT04294628Phase 1Results postedReport a problem
- DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)CompletedNCT04014075Phase 2Results postedReport a problem
- Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]CompletedNCT03734029Phase 3Results postedReport a problem
- DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]CompletedNCT03529110Phase 3Results postedReport a problem
- DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]CompletedNCT03523585Phase 3Results postedReport a problem
- DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung CancerTerminatedNCT03505710Phase 2Results postedReport a problem
- DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)CompletedNCT03384940Phase 2Results postedReport a problem
- DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) ProteinCompletedNCT03368196Phase 1Results postedReport a problem
- Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast CancerCompletedNCT03366428Phase 1Results postedReport a problem
- DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]CompletedNCT03329690Phase 2Results postedReport a problem
- A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)TerminatedNCT03248492Phase 2Results postedReport a problem
- Study of DS-8201a in Subjects With Advanced Solid Malignant TumorsCompletedNCT02564900Phase 1Results postedReport a problem
- A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung CancerWithdrawnNCT07428044Phase 2Report a problem
- A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast CancerWithdrawnNCT06585969Phase 3Report a problem
- Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian PatientsActive, not recruitingNCT06429761Phase 4Report a problem
- T-DXd Therapy for HER2-low Breast Cancer Patients With Brain MetastasesActive, not recruitingNCT06048718Phase 2Report a problem
- Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)Active, not recruitingNCT05710666Phase 2Report a problem
- A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 MutationsActive, not recruitingNCT05048797Phase 3Report a problem
- Phase II Study of T-DX in HER2-positive Breast Cancer Brain MetastasesCompletedNCT04752059Phase 2Report a problem
- Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Active, not recruitingNCT04704934Phase 3Report a problem
- A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)Active, not recruitingNCT04622319Phase 3Report a problem
- A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing TumorsActive, not recruitingNCT04482309Phase 2Report a problem
- Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers AnalysisCompletedNCT04132960Phase 2Report a problem